The largest database of trusted experimental protocols
> Disorders > Sign or Symptom > Pruritus

Pruritus

Pruritus, or itching, is a common and often debilitating symptom associated with a wide range of dermatological and systemic conditions.
It is characterized by an unpleasant sensation that provokes the urge to scratch.
Pruritus can have a significant impact on a person's quality of life, affecting sleep, mood, and daily activities.
Underlying causes can include dry skin, allergic reactions, skin infections, liver or kidney disease, and neuropathic disorders.
Effective management of pruritus often requires a multidisciplinary approach, including the use of topical medications, oral antihistamines, and therapies targeting the underlying condition.
Reserach in this field continues to evolve, with new treatments and management strategies being developed to improve outcomes for those suffering from this distressing symptom.

Most cited protocols related to «Pruritus»

Preliminary items for the 5-D itch scale were derived from (i) modification of the Total Neuropathy Scale4 (link) to be relevant to pruritus rather than neuropathy, (ii) clinical experience by the authors and expert consultants with chronic pruritus under conditions of patient care and clinical trials and (iii) review of the pruritus literature. The preliminary version included both open-ended questions and specific response questions regarding the patient's perception of pruritus. This preliminary version was administered to 21 patients participating in a trial of sertraline for a treatment of cholestatic pruritus.5 (link) Ambiguous items or response choices were revised and response choices selected less than 5% of the time were removed.
The remaining items were grouped into five domains: duration, degree, direction, disability and distribution. Accordingly, the scale was titled the ‘5-D itch scale’ (Fig. 2). The duration, degree and direction domains each included one item, while the disability domain had four items. All items of the first four domains were measured on a five-point Likert scale.
The distribution domain included 16 potential locations of itch, including 15 body part items and one point of contact with clothing or bandages. The preliminary version of the questionnaire also included an ‘other’ item which allowed subjects to write in a response. This led to further refinement of the body part list by the addition of ‘groin’, which was reported by nine subjects. Additional items written in for the free text ‘other’ item were determined by the authors to fit conceptually into items which were already present on the 5-D (e.g. ‘breast’ could be categorized as ‘chest’). Therefore, the instructions were modified to instruct the participant to select the anatomically closest body part for areas that they might not find on the list.
Publication 2009
Breast Chest Cholestasis Disabled Persons Groin Parts, Body Patients Pruritus Sertraline
Dermatitis herpetiformis (DH) is the cutaneous manifestation of gluten-sensitive enteropathy precipitated by exposure to dietary gluten.129 (link) It is characterised clinically by herpetiform clusters of intensely itchy urticated papules and small blisters distributed on the extensor aspects of the elbows and knees and over the buttocks and on the scalp. The commonest age of onset is between the third and fourth decade, though the condition may occur at any age after weaning. Male patients are affected twice as often as female patients. For the majority of patients the disease is lifelong with varying periods of activity, potentially due to varying degrees of dietary adherence.
The major diagnostic criterion for diagnosis is the presence of granular IgA deposits in the dermal papillae of uninvolved perilesional skin as shown by direct immunofluorescence, and the diagnosis should not be made unless this has been confirmed.130 (link)
Less than 10% of patients with DH have symptoms or signs of malabsorption but most have evidence of CD that responds to a GFD and relapses on gluten challenge. Patients with DH present with their skin manifestations and are not usually troubled by the underlying small bowel problem at the time of presentation.129 (link)
131 (link) Abnormality of the small intestinal mucosa with either total or subtotal villous atrophy is found in approximately 70% of patients with DH.132 (link) A further 25% have normal villous architecture with increased IELs.
DH shares with CD an increased risk of developing lymphomas but this seems to be confined to those with severe gut involvement. The risk similarly declines with time on a strict GFD.133 (link)
Due to rash and itch, dapsone is often initiated. More than 70% of patients on a strict GFD are however able to slowly wean off dapsone over a period of 24 months.131 (link)
Publication 2014
Atrophy Buttocks Celiac Disease Dapsone Dermatitis Herpetiformis Diagnosis Diet Elbow Exanthema Gluten Immunofluorescence, Direct Intestinal Mucosa Intestines, Small Knee Lymphoma Malabsorption Syndrome Males Nipples Patients Pruritus Relapse Scalp Skin Skin Manifestations Woman
The Peak Pruritus NRS is a single self‐reported item designed to measure peak pruritus, or ‘worst’ itch, over the previous 24 h based on the following question: ‘On a scale of 0 to 10, with 0 being “no itch” and 10 being “worst itch imaginable”, how would you rate your itch at the worst moment during the previous 24 hours?’
The item was developed with input from clinical dermatology experts and confirmed by patients with AD on the basis of ease of use and understanding.14 Although others have developed similar items,15, 16, 17 this, to our knowledge, is the first comprehensive report summarizing the reliability, validity, responsiveness and threshold of meaningful within‐person change (i.e. response definition) in a single‐item global assessment of peak pruritus. The validation of the Peak Pruritus NRS followed three steps: (i) evaluation of content validity via qualitative interviews, (ii) preliminary assessment of psychometric measurement properties and (iii) confirmation of psychometric measurement properties.
Publication 2019
Patients Pruritus Psychometrics

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2008
Addictive Behavior Alcoholic Intoxication Amphetamines Antidepressive Agents Barbiturates benzedrine Benzodiazepines Central Nervous System Stimulants Chlorpromazine Ethanol Euphoria Hallucinogens Happiness Morphine Narcotic Antagonists Nervousness Opiate Alkaloids Opioids Pentobarbital Pharmaceutical Preparations Phencyclidine Phenothiazines Placebos Pruritus Psychotropic Drugs Pupil Respiratory Rate Sedatives Skin Somnolence Stomach Visual Analog Pain Scale Xerostomia
Content validation was conducted through qualitative analysis of in‐depth one‐to‐one patient interviews to test the relevance, wording, applicability, usability, recall period and response options of the Peak Pruritus NRS in patients with moderate‐to‐severe AD. Interview participants had to be at least 18 years of age, have physician‐reported diagnosis of AD, have had AD for at least 3 years, have had moderate‐to‐severe itching related to AD in the past month, and not have participated in a related clinical trial or focus group in the past 6 months. Moderate‐to‐severe itching related to AD in the past was measured by response to the survey questions (i) ‘At its worst, would you describe the dermatitis‐related itching as mild, moderate, severe or extremely severe?’ (participants must answer ‘moderate’, ‘severe’ or ‘extremely severe’ to qualify) and (ii) ‘When was your last itching episode, as related to atopic dermatitis: in the past 2 weeks, past month, past 2 months or more than 2 months ago?’ (participants must answer ‘in the past 2 weeks’ or ‘in the past month’ to qualify).
We aimed to recruit a sample of patients with diversity of sex, race, ethnicity and level of education. Interviews included concept elicitation about AD symptoms and cognitive debriefing regarding the Peak Pruritus NRS. All interviews were conducted in English by the same pair of skilled, experienced interviewers following a semistructured interview guide, and verbatim responses were transcribed. Patients provided signed written informed consent, and all study materials were reviewed and approved by the institutional review board of RTI International (Raleigh, NC, U.S.A.).
Publication 2019
Cognition Dermatitis Diagnosis Eczema Ethics Committees, Research Ethnicity Interviewers Mental Recall Patients Physicians Pruritus

Most recents protocols related to «Pruritus»

Not available on PMC !

Example 7

20 mg of diethylaminoethyl 5-(2,4-difluorophenyl)salicylate hydrochloride, 3 mg of diethylaminoethyl [R-(E)]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetate hydrochloride, and 5 mg of isopropyl (E)-3-{6-[(E)-1-(4-methylphenyl)-3-pyrrolidine-1-yl-prop-1-enyl]pyridin-2-yl}prop-2-enoate in 0.5 ml of water was applied to the skin on the thorax of a subject every morning and evening (twice per day) until the condition was alleviated. Then 30 mg of diethylaminoethyl acetylsalicylate hydrochloride in 0.5 ml of water was applied to the skin on the thorax of a subject every morning and evening (twice per day) to prevent the recurrence of the condition.

Full text: Click here
Patent 2024
Allergic Conjunctivitis Chest Edan Pruritus pyrrolidine Recurrence Rhinitis, Allergic Rhinorrhea Salicylate Skin
Not available on PMC !

Example 6

10 mg of diethylaminoethyl 2[(2,6-dichlorophenyl)amino]benzene acetate hydrochloride), 3 mg of diethylaminoethyl [R-(E)]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetate, 0.5 mg of (RS)-6-[2-(tert-butylamino)-1-acetyloxyethyl]-2-(acetyloxymethyl)-3-acetyloxypyridine hydrochloride (or pirbuterol triacetate hydrochloride, a HPP of pirbuterol), and 10 mg of diphenhydramine [2-(diphenylmethoxy)-N,N-dimethylethanamine] in 0.5 ml of water was applied to the skin on the thorax of a subject every morning and evening (twice per day) until the condition was alleviated. Then 30 mg of diethylaminoethyl acetylsalicylate hydrochloride and 3 mg of diethylaminoethyl [R-(E)]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetate hydrochloride in 0.5 ml of water was applied to the skin on the thorax of a subject every morning and evening (twice per day) to prevent the recurrence of the condition.

Full text: Click here
Patent 2024
Acetate Allergic Conjunctivitis Benzene Chest Diphenhydramine Edan pirbuterol Pruritus Recurrence Rhinitis, Allergic Rhinorrhea Skin TERT protein, human
The study was approved by the Ethics Committee of Xinqiao Hospital, Army Medical University (Approved No. 2020-146-01). Written informed consents for participating this study were obtained from all participants. The authors affirm that human research participants provided written informed consent for publication of the potentially identifiable medical data included in this article. Participants didn’t receive cash remuneration. ICP was diagnosed according to the Guidelines for diagnosis and treatment of intrahepatic cholestasis of pregnancy from China with the following criteria: unexplainable pruritus; elevated serum bile acids (≥10 μmol/L); no identifiable cause for liver dysfunction; resolution of symptoms and laboratory values postpartum. Exclusion criteria were as follows: preeclampsia, low platelets (HELLP) syndrome, acute fatty liver of pregnancy, active viral hepatitis and primary biliary cirrhosis; patients receiving any antibiotic or probiotics treatment within 1 months; patients with other pregnant complications such as pregnancy diabetes and hypertensive disorders. All pregnant women with ICP were first-visit patients and did not receive any treatment. 50 individuals with ICP and 41 age, BMI and offspring gender matched healthy pregnant women were recruited from Chongqing and Guangdong province of China. There were 30 mild (TBA range 10–39.9 μmol/L) and 20 severe (TBA ≥ 40 μmol/L) ICP patients included. All the characteristics were summarized in Supplementary Tables 1 and 2.
Age, height, body weight, gestation week, birth weight and Apgar score were recorded, and the body mass index (BMI) was calculated. The gestational weeks were strictly matched within 1 week to reduce the impact of gestational week on gut microbiota. Fecal and blood samples were collected after fasting at least 8 h. Fecal samples were stored at −80 °C immediately until further processed. Biochemical parameters were detected by autoanalyzer.
Full text: Click here
Publication 2023
Acute fatty liver of pregnancy Antibiotics Apgar Score Bile Acids Birth Weight BLOOD Blood Platelets Body Weight Diagnosis Ethics Committees, Clinical Feces Gastrointestinal Microbiome Gender HELLP Syndrome Hepatitis Viruses High Blood Pressures Homo sapiens Index, Body Mass Intrahepatic Cholestasis of Pregnancy Patients Pre-Eclampsia Pregnancy Pregnancy in Diabetics Pregnant Women Primary Biliary Cholangitis Probiotics Pruritus Serum
The Sehhaty application was launched under the umbrella of digital transformation initiatives by the Saudi MOH aiming to provide access to several healthcare services for individuals in the Kingdom. These services included consultations, PCR testing for SARS-CoV-2, booking COVID-19 vaccine appointments, and reporting COVID-19 vaccines side-effects through the option of manual entering and/or drop box option selection (16 ). Indeed, the Sehhaty application offers a checkbox option to report symptoms for the received vaccine. The following symptoms were available for users to select from in the following order: injection site itching, wheezing, fatigue, hoarseness, low fever, anxiety, fever above or below 39°C, heartburn, injection site swelling, headache, loss of consciousness, nausea, injection site redness, injection site pain, itchiness other than injection site, seizure, dizziness, difficulty or shortness of breath, sleep disruption, swelling of lips, face, and throat, and intensive care unit (ICU) admission. The study participants were provided with a checkbox list that included all of the aforementioned side-effects and were given the option to select from the list if they experienced any of them. Another helpful feature was the registration of the date and the start of symptoms, which allowed for filtering and limiting the studied side-effects to be within a window of 14 days post-vaccination (7 (link)). Participants' demographics data were collected and included: age, gender, nationality, region, COVID-19 vaccine type, the number of vaccine doses, date of vaccination, and date of ICU admission.
Full text: Click here
Publication 2023
Anxiety COVID-19 Vaccines Dyspnea Erythema Face Fatigue Fever Gender Headache Heartburn Hoarseness Lip Nausea Pain Pharynx Pruritus SARS-CoV-2 Seizures Sleep Vaccination Vaccines
The study included all vaccinated female and male individuals in Saudi Arabia of any ethnicity, who were 12–96 years of age and spontaneously self-reported their side-effects through the Sehhaty app after receiving at least one dose of the three available COVID-19 vaccines: Pfizer–BioNTech (BNT162b2), Oxford–AstraZeneca (ChAdOx1-S), and/or Moderna (mRNA-1273) within 14 days of receiving COVID-19 vaccination over the period from 17th December 2020 to 31st December 2021 (7 (link)). The ICU records were considered post vaccine events if they happened within 14 days post COVID-19 vaccination. The exclusion criteria entailed individuals with wrong or missing data entry and/or misidentified unique IDs, individuals who are under 12 years or above 96 years old, those who did not receive COVID-19 vaccination, or who received COVID-19 vaccines other than Pfizer–BioNTech, Oxford–AstraZeneca or Moderna vaccines, and those who reported their side-effects outside of the 14-day window. We excluded those with pre-existing comorbidities and/or autoimmune diseases, as they could confound the results of the self-reported vaccines adverse events. The primary objective was to determine the patterns of minor side-effects: injection site (itchiness, pain, reaction, redness, swelling, and other), anxiety, dizziness, fever above or below 39°C, headache, hoarseness, itchiness other than injection site, loss of consciousness, nausea, heartburn, sleep disruption, and fatigue. In addition, we examined the pattern of reported major COVID-19 vaccine side-effects: seizures, shortness of breath, wheezing, swelling of lips, face, and throat, ICU admission, and loss of consciousness. The AEs were classified as local, systemic, or allergic, or as mild or moderate.
Full text: Click here
Publication 2023
2019-nCoV Vaccine mRNA-1273 Anxiety Autoimmune Diseases BNT162B2 ChAdOx1 nCoV-19 COVID-19 Vaccines COVID 19 Dyspnea Erythema Ethnicity Face Fatigue Fever Headache Heartburn Hoarseness Lip Males Nausea Pain Pharynx Pruritus Seizures Sleep Vaccination Vaccine, Pfizer Covid-19 Vaccines Woman

Top products related to «Pruritus»

Sourced in United States, China, Germany, United Kingdom, Canada, Japan, France, Italy, Switzerland, Australia, Spain, Belgium, Denmark, Singapore, India, Netherlands, Sweden, New Zealand, Portugal, Poland, Israel, Lithuania, Hong Kong, Argentina, Ireland, Austria, Czechia, Cameroon, Taiwan, Province of China, Morocco
Lipofectamine 2000 is a cationic lipid-based transfection reagent designed for efficient and reliable delivery of nucleic acids, such as plasmid DNA and small interfering RNA (siRNA), into a wide range of eukaryotic cell types. It facilitates the formation of complexes between the nucleic acid and the lipid components, which can then be introduced into cells to enable gene expression or gene silencing studies.
Sourced in United States, Austria, Japan, Cameroon, Germany, United Kingdom, Canada, Belgium, Israel, Denmark, Australia, New Caledonia, France, Argentina, Sweden, Ireland, India
SAS version 9.4 is a statistical software package. It provides tools for data management, analysis, and reporting. The software is designed to help users extract insights from data and make informed decisions.
Sourced in United States, China, Japan, Germany, United Kingdom, Canada, France, Italy, Australia, Spain, Switzerland, Netherlands, Belgium, Lithuania, Denmark, Singapore, New Zealand, India, Brazil, Argentina, Sweden, Norway, Austria, Poland, Finland, Israel, Hong Kong, Cameroon, Sao Tome and Principe, Macao, Taiwan, Province of China, Thailand
TRIzol reagent is a monophasic solution of phenol, guanidine isothiocyanate, and other proprietary components designed for the isolation of total RNA, DNA, and proteins from a variety of biological samples. The reagent maintains the integrity of the RNA while disrupting cells and dissolving cell components.
Sourced in United States, China, Germany, Japan, United Kingdom, France, Canada, Italy, Australia, Switzerland, Denmark, Spain, Singapore, Belgium, Lithuania, Israel, Sweden, Austria, Moldova, Republic of, Greece, Azerbaijan, Finland
Lipofectamine 3000 is a transfection reagent used for the efficient delivery of nucleic acids, such as plasmid DNA, siRNA, and mRNA, into a variety of mammalian cell types. It facilitates the entry of these molecules into the cells, enabling their expression or silencing.
Sourced in United States, Germany, United Kingdom, Italy, Sao Tome and Principe, Spain, Macao, Canada, Brazil, France, Australia, Austria
Histamine is a laboratory equipment product manufactured by Merck Group. It is a chemical compound used in various research and analytical applications. Histamine plays a crucial role in biological processes and is commonly utilized in laboratories for testing and analysis purposes.
Sourced in United States, China, Germany, United Kingdom, Switzerland, Japan, France, Italy, Spain, Austria, Australia, Hong Kong, Finland
The Dual-Luciferase Reporter Assay System is a laboratory tool designed to measure and compare the activity of two different luciferase reporter genes simultaneously. The system provides a quantitative method for analyzing gene expression and regulation in transfected or transduced cells.
Sourced in United States, Germany, United Kingdom, China, France, Macao, Sao Tome and Principe, Switzerland, Italy, Canada, Japan, Spain, Belgium, Israel, Brazil, India
Chloroquine is a laboratory chemical primarily used as a research tool in biochemical and cell biology applications. It is a white, crystalline solid that is soluble in water. Chloroquine is commonly used in experiments to study cellular processes, such as autophagy and endocytosis, by inhibiting the function of lysosomes. Its core function is to serve as a research reagent for scientific investigations, without making any claims about its intended use.
Sourced in United States, China, United Kingdom, Germany, Japan, France, Canada, Switzerland, Denmark, Belgium, Italy, Australia, Singapore, Spain, Colombia, Sweden, Netherlands, New Zealand, Poland, Pakistan, Lithuania
Lipofectamine RNAiMAX is a transfection reagent designed for efficient delivery of small interfering RNA (siRNA) and short hairpin RNA (shRNA) into a wide range of cell types. It is a cationic lipid-based formulation that facilitates the uptake of these nucleic acids into the target cells.
Sourced in Japan, China, United States, France, Germany, Switzerland, Canada, Sweden, Italy, Puerto Rico, Singapore
The PrimeScript RT reagent kit is a reverse transcription kit designed for the synthesis of first-strand cDNA from RNA templates. The kit includes RNase-free reagents and enzymes necessary for the reverse transcription process.
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.

More about "Pruritus"

Pruritus, also known as itching, is a common and often debilitating symptom associated with a wide range of dermatological and systemic conditions.
This unpleasant sensation triggers the urge to scratch, which can significantly impact a person's quality of life, affecting sleep, mood, and daily activities.
Underlying causes of pruritus can include dry skin, allergic reactions, skin infections, liver or kidney disease, and neuropathic disorders.
Effective management of pruritus often requires a multidisciplinary approach, including the use of topical medications, such as Lipofectamine 2000 and Lipofectamine 3000, oral antihistamines like Histamine, and therapies targeting the underlying condition.
Research in this field continues to evolve, with new treatments and management strategies, including the use of TRIzol reagent, Dual-Luciferase Reporter Assay System, Chloroquine, and Lipofectamine RNAiMAX, being developed to improve outcomes for those suffering from this distressing symptom.
PubCompare.ai, a platform that leverages AI-driven protocol optimization, can enhance pruritus research by helping researchers locate the best protocols and products from literature, pre-prints, and patents with ease.
The platform compares data to identify the most effective solutions for pruritus research needs, utilizing tools like SAS version 9.4 and the PrimeScript RT reagent kit.
By incorporating these insights and technologies, researchers can work towards better understanding and managing pruritus, ultimately improving the quality of life for those affected by this condition.